Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PDS Biotechnology Corp

Get SEC filing alerts via email and in your feed for PDS Biotechnology Corp

PDSB EDGE

PDS Biotechnology Corp

About PDS Biotechnology Corp

PDS Biotechnology develops innovative immunotherapies targeting cancer and infectious diseases. Its core platform, Versamune, stimulates potent, tumor-specific T cell responses with a favorable safety profile. The company focuses on cancer treatments, including HPV-related and resistant cancers, and vaccines for infectious diseases like influenza. Its business model combines proprietary immunotherapy platforms with strategic collaborations to advance targeted, immune-based therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PDS Biotechnology Corp

1
1
PDS Biotechnology Corp PDS Biotechnology Reports $7.3 Million Net Loss in Q1 2026, Focuses on Clinical Pipeline

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
PDS Biotechnology Corp PDS Biotechnology Corp. Reports $34.5 Million Net Loss for 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
PDS Biotechnology Corp PDS Biotechnology Corporation Reports Decreased Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PDS Biotechnology Corp PDS Biotechnology Reports $9.4 Million Net Loss in Q2 2025, Focuses on Clinical Trials

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PDS Biotechnology Corp PDS Biotechnology Reports $8.5 Million Net Loss in Q1 2025, Focuses on Clinical Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PDS Biotechnology Corp PDS Biotechnology Reports $37.6 Million Net Loss for 2024, Sees Improvement from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
PDS Biotechnology Corp PDS Biotechnology Reports Financial Results for Q3 2024, Expects Funding Challenges Ahead

Via official filing (AI summary) | over 1 year ago | 0 comments